{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:22:51Z","timestamp":1792664571440,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022896","name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2016274"],"award-info":[{"award-number":["2016274"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eururo.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:09:46Z","timestamp":1770062986000},"page":"446-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bacillus Calmette-Gu\u00e9rin Plus Mitomycin Versus Bacillus Calmette-Gu\u00e9rin Alone for Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve Non\u2013muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4094-401X","authenticated-orcid":false,"given":"Dickon","family":"Hayne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ischia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnesh K.","family":"Srivastav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Grummet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Bastick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma K.","family":"Beardsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mitterdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomik","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Hawks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve P.","family":"McCombie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.01.009_b0005","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2026.01.009_b0010","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical BCG vs mitomycin-C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrences and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette\u2010Guerin is superior to mitomycin C in reducing tumour recurrence in high\u2010risk superficial bladder cancer: a meta\u2010analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.01.009_b0020","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.01.009_b0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0030","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0035","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0022-5347(01)65396-5","volume":"156","author":"Pawinski","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/ajco.14001","article-title":"Systemic treatment of advanced and metastatic urothelial cancer: the landscape in Australia","volume":"19","author":"Gurney","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.009_b0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.01.009_b0050","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1464-410X.2012.11390.x","article-title":"Intravesical chemotherapy plus bacille Calmette-Gu\u00e9rin in non-muscle invasive bladder cancer: a systematic review with meta-analysis","volume":"111","author":"Houghton","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.01.009_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urolonc.2021.09.022","article-title":"Critical shortage in BCG immunotherapy: How did we get here and where will it take us?","volume":"40","author":"Harvey","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.01.009_b0060","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2026.01.009_b0065","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12885-015-1431-6","article-title":"BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)","volume":"15","author":"Hayne","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2026.01.009_b0070","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.01.009_b0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0080","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0085","unstructured":"US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. August 2024."},{"issue":"5_suppl","key":"10.1016\/j.eururo.2026.01.009_b0090","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1200\/JCO.2025.43.5_suppl.717","article-title":"Global real-world patients characteristics, treatment patterns, and impact of BCG shortage in patients with high-risk non-muscle invasive bladder cancer","volume":"43","author":"Bedke","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.009_b0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/UA.UA_115_17","article-title":"Prognostic impact of bacillus Calmette-Gu\u00e9rin interruption at the time of induction and consolidation","volume":"9","author":"Alhogbani","year":"2017","journal-title":"Urol Ann"},{"key":"10.1016\/j.eururo.2026.01.009_b0100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/ajco.13933","article-title":"Fremantle protocol: multicenter clinical outcomes for a pragmatic protocol for intravesical bacillus Calmette-Guerin","volume":"19","author":"Tan","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.009_b0105","first-page":"106","article-title":"Comparison of single monthly instillations of intra-vesical bacillus Calmette-Guerin maintenance therapy with Southwest Oncology Group regimen in non-muscle invasive bladder cancer patients\u2014A retrospective analysis in a single institute","volume":"19","author":"Lashay","year":"2021","journal-title":"Urol J"},{"key":"10.1016\/j.eururo.2026.01.009_b0110","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0115","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.009_b0125","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.01.009_b0130","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1002\/cncr.33792","article-title":"The impact of the social construct of race on outcomes among bacille Calmette-Gu\u00e9rin-treated patients with high-risk non-muscle\u2013invasive bladder cancer in an equal-access setting","volume":"127","author":"Lawler","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.01.009_b0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.21037\/tau.2018.08.19","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin for bladder cancer: are all the strains equal?","volume":"8","author":"D'Andrea","year":"2019","journal-title":"Transl Androl Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T21:47:35Z","timestamp":1778017655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826000151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0302283826000151"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.009","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette-Gu\u00e9rin Plus Mitomycin Versus Bacillus Calmette-Gu\u00e9rin Alone for Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve Non\u2013muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}